VivoSim Labs Inc (VIVS): Bathi resik saben saham (EPS TTM)

Geopolitical risks and disruptions in Asian logistics are complicating clinical tests for VivoSim Labs Inc (VIVS). On GURU.Markets, the 12-month net income per share trend captures the business's adaptation, where -3.51 shows the value of this parameter. VivoSim Labs Inc is scaling diagnostic devices for the pharmaceutical industry, leveraging its high authority in creating live organ models for safe drug development.
Rincian analitis lan laporan data perusahaan VivoSim Labs (VIVS)

VivoSim Labs Inc (VIVS) is optimizing costs by outsourcing component production and clinical trials to external partners. The efficiency of such outsourcing directly determines the final financial result, which serves as the basis for calculating earnings per share. This indicator measures the real fundamental return of the business, adjusted for the total volume of issuance. It allows for a distinction between objective profitability and market expectations. The 12-month EPS history visualizes the capital's resilience to operational risks.